NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $87.97 +0.08 (+0.09%) As of 01/17/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings About SPDR S&P Biotech ETF (NYSEARCA:XBI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$87.85▼$88.8650-Day Range$86.66▼$103.5052-Week Range$81.14▼$105.47Volume7.37 million shsAverage Volume9.40 million shsMarket Capitalization$6.71 billionAssets Under Management$6.08 billionDividend Yield0.02%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.55%0.51%0.52%Other Expenses0.00%0.30%0.49%0.57%0.54%Total Expense0.35%0.70%0.71%0.73%0.71%Fee Waiver0.00%-0.45%-0.51%-0.66%-0.56%Net Expense0.35%0.61%0.61%0.58%0.59% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XBI ETF News HeadlinesSPDR S&P Biotech ETF declares quarterly distribution of $0.0027December 23, 2024 | msn.comLitecoin Price Forecast: Whales invest $950M in 73-day buying spree amid LTC ETF approval rumoursNovember 28, 2024 | fxstreet.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. January 20, 2025 | Crypto 101 Media (Ad)Biotech ETF (XBI) ended a diagonal: Looking for buying dipsNovember 27, 2024 | fxstreet.comBiotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)November 19, 2024 | seekingalpha.comSPDR Series Trust SPDR S&P Biotech ETF (ARCA:XBI), Short Interest ReportNovember 19, 2024 | benzinga.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $90.06 at the beginning of the year. Since then, XBI shares have decreased by 2.3% and is now trading at $87.97. View the best growth stocks for 2025 here. Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's top institutional investors include Howard Capital Management Group LLC (0.33%), Wealth Enhancement Advisory Services LLC (0.16%), Edge Wealth Management LLC (0.14%) and SG Americas Securities LLC (0.14%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotech Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings152 Fund Statistics Assets Under Management$6.08 billion Average Daily Volume$9.02 million Discount/Premium-0.03% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume47,222 Put Options33,778 Call Options13,444 Short Interest56,670,000 shs Miscellaneous Outstanding Shares76,220,000Beta1.11 Creation Unit50,000 Creation Fee$250.00 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Top 10 XBI HoldingsNeurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 2.73%United Therapeutics (NASDAQ:UTHR)Holding Weight: 2.49%Natera (NASDAQ:NTRA)Holding Weight: 2.48%Incyte (NASDAQ:INCY)Holding Weight: 2.46%AbbVie (NYSE:ABBV)Holding Weight: 2.45%Gilead Sciences (NASDAQ:GILD)Holding Weight: 2.44%Amgen (NASDAQ:AMGN)Holding Weight: 2.43%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 2.41%Insmed (NASDAQ:INSM)Holding Weight: 2.41%Vaxcyte (NASDAQ:PCVX)Holding Weight: 2.37%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is ...Brownstone Research | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.